Envestnet Asset Management Inc. Increases Stock Holdings in First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH)

Envestnet Asset Management Inc. lifted its position in First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) by 14.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,799 shares of the company’s stock after purchasing an additional 2,396 shares during the quarter. Envestnet Asset Management Inc. owned about 3.42% of First Trust Nasdaq Pharmaceuticals ETF worth $517,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. LPL Financial LLC grew its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 9.3% in the fourth quarter. LPL Financial LLC now owns 55,876 shares of the company’s stock valued at $1,507,000 after purchasing an additional 4,776 shares during the period. Cambridge Investment Research Advisors Inc. raised its position in First Trust Nasdaq Pharmaceuticals ETF by 19.2% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 16,567 shares of the company’s stock valued at $455,000 after purchasing an additional 2,663 shares during the period. Summit Investment Advisors Inc. raised its position in First Trust Nasdaq Pharmaceuticals ETF by 13.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,173 shares of the company’s stock valued at $382,000 after purchasing an additional 1,633 shares during the period. Vivaldi Capital Management LP raised its position in First Trust Nasdaq Pharmaceuticals ETF by 15.6% in the fourth quarter. Vivaldi Capital Management LP now owns 8,677 shares of the company’s stock valued at $243,000 after purchasing an additional 1,171 shares during the period. Finally, NBC Securities Inc. raised its position in First Trust Nasdaq Pharmaceuticals ETF by 21,400.0% in the first quarter. NBC Securities Inc. now owns 1,075 shares of the company’s stock valued at $29,000 after purchasing an additional 1,070 shares during the period.

First Trust Nasdaq Pharmaceuticals ETF Stock Up 0.5%

NASDAQ:FTXH opened at $26.55 on Wednesday. First Trust Nasdaq Pharmaceuticals ETF has a 52 week low of $23.28 and a 52 week high of $29.72. The company has a market capitalization of $14.60 million, a P/E ratio of 14.51 and a beta of 0.70. The stock’s fifty day moving average is $26.10 and its two-hundred day moving average is $26.37.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Thursday, June 26th were given a $0.0892 dividend. The ex-dividend date was Thursday, June 26th. This represents a $0.36 dividend on an annualized basis and a yield of 1.3%.

First Trust Nasdaq Pharmaceuticals ETF Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.